Setmelanotide (Imcivree®) was approved in 2020 for obesity due to proopiomelanocortin (POMC), leptin receptor (LEPR), or PCSK1 deficiency, and later for Bardet–Biedl syndrome [78]. Here, POMC is linked to obesity due to melanocortin 4 receptor deficiency.